Fu Y, et al. - This study draws on data from a large electronic medical record database from four tertiary hospitals in major cities in China from 2009 to 2016 to compare the features of benign prostatic hyperplasia (BPH) patients receiving either the 5-alpha-reductase inhibitor finasteride in combination with an alpha blocker or an alpha blocker monotherapy in clinical practice. Eligibility criteria included BPH patients aged ≥ 50 years with ≥ 1 alpha blocker fill on/after the first BPH diagnosis. Compared to those using alpha blocker monotherapy, Chinese BPH patients using finasteride/alpha blocker combination therapy were older and had a higher comorbidity burden (ie hypertension, cardiovascular disease, and diabetes).